Dauba Ambre, Delalande Anthony, Kamimura Hermes A S, Conti Allegra, Larrat Benoit, Tsapis Nicolas, Novell Anthony
Université Paris-Saclay, CEA, CNRS, Inserm, BioMaps, Service Hospitalier Frédéric Joliot, 91401 Orsay, France.
Centre de Biophysique Moléculaire and Université d'Orléans, CNRS-UPR 4301, 45071 Orléans, France.
Pharmaceutics. 2020 Nov 21;12(11):1125. doi: 10.3390/pharmaceutics12111125.
The blood-brain barrier is the primary obstacle to efficient intracerebral drug delivery. Focused ultrasound, in conjunction with microbubbles, is a targeted and non-invasive way to disrupt the blood-brain barrier. Many commercially available ultrasound contrast agents and agents specifically designed for therapeutic purposes have been investigated in ultrasound-mediated blood-brain barrier opening studies. The new generation of sono-sensitive agents, such as liquid-core droplets, can also potentially disrupt the blood-brain barrier after their ultrasound-induced vaporization. In this review, we describe the different compositions of agents used for ultrasound-mediated blood-brain barrier opening in recent studies, and we discuss the challenges of the past five years related to the optimal formulation of agents.
血脑屏障是实现高效脑内药物递送的主要障碍。聚焦超声联合微泡是一种靶向且非侵入性破坏血脑屏障的方法。在超声介导的血脑屏障开放研究中,已对许多市售超声造影剂以及专门为治疗目的设计的制剂进行了研究。新一代的声敏剂,如液芯微滴,在超声诱导其汽化后也有可能破坏血脑屏障。在本综述中,我们描述了近期研究中用于超声介导血脑屏障开放的制剂的不同组成,并讨论了过去五年中与制剂最佳配方相关的挑战。